Inito has raised $29 million in Series B funding led by Bertelsmann India Investments and Fireside Ventures. The round brings Inito’s total funding to approximately $45 million.
The company will use the funding to invest in and develop AI-engineered antibodies to enable new types of at-home tests and improve the accuracy of existing ones. Inito will also scale manufacturing and expand globally to meet demand across the United States and new international markets.
Inito launched its first fertility monitor in 2021 to make quantitative fertility hormone testing possible at home. The device allows women to measure estrogen, luteinizing hormone, progesterone metabolite PdG, and follicle-stimulating hormone on a single test strip. Inito’s AI models interpret these levels to reveal fertility hormone patterns, track fertile days, and confirm ovulation.
Standard at-home ovulation tests predict fertile days by tracking estrogen and luteinizing hormone but do not measure progesterone metabolite PdG, which confirms ovulation. Inito has analyzed more than 30 million fertility hormone data points since 2021.
Traditional antibodies used in lab or home tests are grown inside animals and screened manually in the lab, which can be slow and expensive. Conventional antibodies also lack the sensitivity to make at-home tests for a large number of biomarkers.
Inito’s approach uses AI to predict how proteins fold in 3D, design synthetic antibodies, and test millions of variants virtually before making one in the lab. The company is using these methods in research and development, with its wet lab showing results.
Inito is expanding its vision beyond fertility tracking. The company’s reader and app will soon power tests for pregnancy, menopause, and broader at-home health monitoring. The long-term roadmap includes measuring and interpreting hormones across a lifetime, including pregnancy progression, menopause, and endocrine markers such as testosterone.
Inito previously raised $6 million in funding led by Fireside Ventures and $9 million from Y Combinator, former Nurx CEO Varsha Rao, and physicians and family offices.
